Substance use disorders are treatable health conditions, yet people affected by them are still frequently described as weak, irresponsible, dangerous, dishonest or morally flawed.
Those assumptions are not harmless.
Stigma can influence whether somebody admits that they need help, whether a family responds with support or punishment, how a patient is treated in a medical setting, whether evidence-based medication is accepted, and whether a person in recovery feels able to return to work, rebuild relationships and participate openly in society.
SAMHSA identifies shame, negative beliefs and discriminatory practices as barriers that can prevent people with substance use disorders from seeking services or even disclosing that they are in recovery.
Stigma can also operate internally. After repeatedly hearing that addiction means somebody is “bad,” “weak” or incapable of change, a person may begin to apply the same judgment to themselves.
That can reduce hope precisely when hope and engagement with treatment are most important.
Reducing stigma does not mean denying the serious consequences that can accompany substance use.
Substance use disorders can affect health, relationships, finances, parenting, employment and public safety. People remain responsible for addressing harmful behavior.
The difference is that accountability and medical treatment do not require humiliation.
A person can be held accountable while still being treated as a human being with a health condition that deserves evidence-based care.
This guide explains where substance-use stigma comes from, how language influences attitudes, how stigma appears inside healthcare and families, why medications for opioid use disorder are sometimes unfairly stigmatized, and what individuals, healthcare professionals, employers, families and communities can do differently.
How stigma affects treatment and recovery, which terms are more respectful and clinically accurate, how medication stigma can harm people with opioid use disorder, and practical ways to replace judgment with evidence-based support.
Prepared for medical review by Dr. Fergus Law, BSc, MBChB, FRCPsych
Consultant Psychiatrist specialising in substance misuse and addiction psychiatry
Review status: Pending clinical approval
View Dr Fergus Law’s Clinical & Scientific Profile →What Is Substance Use Disorder Stigma?
Stigma occurs when a characteristic or diagnosis becomes associated with negative stereotypes and those stereotypes are applied to the person.
With substance use disorders, common stereotypes include beliefs that people are irresponsible, dangerous, dishonest, unreliable, morally weak or incapable of recovery.
These stereotypes can then influence emotions and behavior.
Somebody may feel fear, anger or disgust toward a person with addiction. An employer may refuse to consider somebody in recovery. A clinician may spend less time listening to a patient. A family may treat every problem as evidence that the person is “an addict.”
Stigma and Discrimination Are Related, but Not Identical
Stigma describes the labeling, stereotyping and negative social meaning attached to a condition.
Discrimination refers more directly to actions that disadvantage somebody because of that stigma.
A stigmatizing belief can therefore exist without an immediate discriminatory act, while repeated stigmatizing beliefs across institutions can contribute to structural discrimination.
A person may have a substance use disorder. The person is not the disorder.
Different Types of Substance Use Stigma
Stigma is not only something that happens when one person insults another. It can operate socially, structurally and internally.
Public Stigma
Negative beliefs and stereotypes held by members of the public toward people with substance use disorders.
Structural Stigma
Policies, institutional practices or systems that create disadvantages for people affected by substance use disorders.
Internalized Stigma
When somebody begins to accept negative stereotypes about addiction and applies them to themselves.
Anticipated Stigma
Fear that others will judge, reject or discriminate against someone if their substance use disorder becomes known.
These Forms of Stigma Can Reinforce One Another
A person who repeatedly hears negative public messages may begin to expect discrimination.
That expectation may cause them to hide the problem from a doctor or family member.
Avoiding treatment can then allow the disorder to become more severe, creating more visible consequences and reinforcing public stereotypes.
Research consistently identifies substance-use stigma as an important barrier to treatment engagement and harm-reduction services.
Where Addiction Stigma Comes From
Substance use disorders sit at the intersection of medicine, behavior, law, family conflict and social expectations.
That makes stigma particularly complex.
Unlike many other health conditions, substance use can involve behaviors that genuinely hurt other people.
Families may experience broken promises, financial loss, impaired parenting, unsafe driving or repeated crises.
Recognizing addiction as a health condition does not require pretending those consequences do not exist.
The mistake is turning harmful behavior into a permanent definition of the entire person.
“They Should Just Stop”
Addiction has historically been framed as evidence of weak character or inadequate willpower.
“People With Addiction Are Dangerous”
Highly visible crises can create the false assumption that every person with a substance use disorder behaves in the same way.
One Label Replaces the Person
Complex people become described only as “addicts,” “junkies” or “drug users,” obscuring their relationships, work, abilities and recovery potential.
Choice and Addiction Are Not an Either/Or Question
People make choices around substance use, particularly during early exposure.
At the same time, repeated substance exposure can interact with learning, reward, stress, withdrawal, environment, mental health and biological vulnerability.
A useful medical framework can therefore recognize both agency and neurobehavioral adaptation.
Treatment helps people regain greater control over behavior rather than assuming that the only missing ingredient is shame.
Why Language Matters in Addiction
Language is not only about politeness.
The words used to describe substance use can influence how other people interpret responsibility, prognosis and appropriate treatment.
NIDA and NIH recommend person-first and non-stigmatizing terminology in general health communication.
Person-first language describes what somebody has rather than defining what somebody is.
“An Addict”
The condition becomes the person’s identity.
“A Person With Opioid Use Disorder”
The diagnosis is one part of a whole human being.
This does not mean an individual is prohibited from describing themselves using language that has personal meaning.
For example, some people in mutual-help groups personally use words such as “addict” or “alcoholic” as part of their recovery identity.
Public-facing medical communication is different.
Healthcare professionals, journalists and organizations should avoid imposing stigmatizing identity labels on other people.
Overcoming Stigma, Ending Discrimination
This SAMHSA educational webcast discusses how stigma and negative perceptions affect people with substance use disorders and what healthcare professionals can do differently.
SAMHSA educational webcast on substance-use stigma and discrimination.
Words to Avoid and Better Alternatives
Clinically accurate language can reduce unnecessary judgment while still describing substance use clearly.
Person-first language is a useful default in clinical communication. When speaking directly with an individual, it is also reasonable to ask how they prefer their recovery experience to be described.
How Stigma Can Delay Addiction Treatment
Treatment cannot help somebody who feels unable to enter it.
Stigma can create several barriers before a person ever reaches a clinic.
What Might Somebody Fear?
- “My doctor will stop listening to me.”
- “My family will never trust me again.”
- “People at work will think I am unreliable.”
- “Everyone will see me as an addict forever.”
- “If I take medication for addiction, people will say I am still using drugs.”
- “If I return to use, everyone will say treatment failed.”
These concerns can become especially powerful in professions, families or communities where addiction is strongly associated with shame.
Systematic reviews identify stigma among the social and structural barriers that can affect access to and persistence in substance-use treatment.
Substance Use Stigma Inside Healthcare
Healthcare professionals are not immune to the attitudes found in wider society.
Research has documented stigmatizing attitudes toward people with substance use disorders among healthcare professionals and trainees.
This matters because the healthcare system is often where somebody first has an opportunity to disclose that substance use has become a problem.
Dismissive Language
Describing patients as “drug seekers,” “abusers” or difficult can shape how later clinicians interpret their symptoms.
Symptoms May Be Discounted
A history of substance use should not cause every complaint to be automatically interpreted as manipulation or intoxication.
Evidence-Based Care May Be Delayed
Stigma toward addiction or medication treatment can affect willingness to offer appropriate services.
Compassion Is Not the Same as Ignoring Risk
Clinicians still need boundaries, accurate history, toxicology when appropriate, safe prescribing and assessment of risk.
Non-stigmatizing care does not require abandoning clinical judgment.
It means applying that judgment consistently and respectfully.
Instead of:
“Why won’t this patient behave?”
Consider:
“What biological, psychological, social and treatment barriers
are maintaining this pattern?”
Stigma Around Medications for Opioid Use Disorder
Some of the most persistent stigma in addiction treatment is directed not only at the patient but at the treatment itself.
Methadone and buprenorphine are sometimes described as “replacing one drug with another.”
That description is misleading.
Medication treatment for opioid use disorder is structured medical care. Methadone, buprenorphine and naltrexone have different pharmacology, but all are legitimate medications used for opioid use disorder in appropriate patients.
Full Agonist Treatment
Methadone provides controlled long-acting opioid receptor activation and can reduce withdrawal, craving and illicit opioid use.
Partial Agonist Treatment
Buprenorphine partially activates mu-opioid receptors and can suppress withdrawal and craving.
Antagonist Treatment
Naltrexone occupies opioid receptors without activating them and blocks opioid effects while effective antagonist concentrations are maintained.
A person using naltrexone is not “more recovered” than somebody using buprenorphine or methadone. Likewise, taking methadone or buprenorphine does not mean somebody has simply exchanged one addiction for another.
Treatment Should Be Judged by Clinical Outcomes
A more useful discussion considers safety, treatment retention, illicit opioid use, overdose risk, functioning, patient preference and overall quality of life.
The appropriate medication can differ between patients.
Reducing medication stigma means allowing those decisions to be based on clinical evidence and individual circumstances rather than social status attached to a particular medication.
Read FDA Information on OUD Medications →Naltrexone, Long-Acting Treatment and Individual Choice
Some patients prefer an opioid-antagonist approach to recovery.
Naltrexone differs from methadone and buprenorphine because it does not activate the mu-opioid receptor.
Instead, it occupies opioid receptors and can block or substantially reduce the effects of opioid agonists while adequate blockade is present.
This pharmacology may appeal to patients who want an antagonist-based approach after completing opioid withdrawal.
Naltrexone does not produce the same opioid agonist effect as methadone or buprenorphine.
A patient who remains physically dependent on opioids must complete appropriate opioid-free preparation before naltrexone begins.
Longer-acting formulations can reduce the need to remember a tablet every day.
Antagonist treatment should not be described as making overdose impossible or guaranteeing recovery.
What About Naltrexone Implants?
Sustained-release naltrexone implants have been studied and used in some countries and treatment settings.
Implant products can differ in dose, release profile, duration, manufacturing and regulatory status.
In the United States, the FDA-approved long-acting naltrexone formulation for opioid use disorder is extended-release intramuscular naltrexone. Naltrexone implants are not FDA-approved in the United States.
Choosing an antagonist such as naltrexone can be a legitimate treatment preference, but it should not be marketed by suggesting that patients using methadone or buprenorphine are somehow less successful or less “clean.”
Why a Consultation Matters
Naltrexone cannot simply be started because somebody decides they no longer want opioids.
The clinician needs to understand which opioids are being used, whether methadone or buprenorphine is involved, how physically dependent the person is, when opioids were last used, relevant medical conditions and whether appropriate withdrawal preparation has been completed.
Starting naltrexone too early can precipitate severe withdrawal.
Interested in an Antagonist-Based Recovery Approach?
DeBinge can explain long-acting naltrexone, preparation requirements, counselling and recovery planning without judging people for the treatment approach they have used previously.
A consultation is intended to determine whether this approach is appropriate for the individual — not to assume that one medication is the correct option for everybody.
Reducing Stigma Within Families
Families can be one of the strongest sources of recovery support.
They can also become an important source of shame.
This is often complicated by the fact that family members may have been genuinely harmed by the person’s substance use.
Reducing stigma does not mean asking relatives to forget what happened or immediately restore trust.
It means separating the person’s worth from the behavior that caused harm.
“I Cannot Give You Money While You Are Using.”
This communicates a practical boundary around behavior.
“You Are a Junkie and Will Never Change.”
This defines the person by a stigmatizing identity and predicts permanent failure.
Support Does Not Mean Enabling
Families can encourage treatment, refuse to finance substance use, protect children, enforce household boundaries and call emergency services when necessary.
None of those actions require humiliation.
“I love you. I will support treatment and recovery. I cannot support behavior that is unsafe for you or the rest of the family.”
Workplace, Media and Community Stigma
Recovery does not happen only inside treatment.
People return to workplaces, families, education and communities. The response they receive can influence whether recovery feels compatible with ordinary life.
Workplace
An employee in recovery may fear that disclosure will permanently change how colleagues or managers see them.
Employers should distinguish legitimate safety requirements from broad assumptions that anybody with a history of substance use is unreliable.
Media
News coverage can reinforce stigma through dehumanizing photographs, sensational language and descriptions that present addiction only through crime or social decline.
Balanced reporting can acknowledge serious harms while also showing treatment, recovery and the diversity of people affected.
Community
Community stigma can influence support for treatment services, recovery housing, harm-reduction programs and reintegration of people after treatment.
Familiarity with real recovery stories can challenge the assumption that people with substance use disorders are permanently defined by their worst period.
Internalized Stigma and Shame
A person does not need somebody else in the room to experience stigma.
After years of hearing negative messages about addiction, people can begin repeating those messages to themselves.
Guilt and Shame Are Not the Same
Guilt can focus on a specific behavior: “I did something harmful and need to repair it.”
Shame is more global: “I am fundamentally bad and do not deserve recovery.”
Recovery may require taking responsibility for past behavior while refusing to treat that behavior as proof of permanent worthlessness.
A 2024 systematic review concluded that substance-use self-stigma is an important barrier to treatment and harm-reduction engagement and evaluated psychosocial approaches intended to reduce it.
Practical Ways to Challenge Self-Stigma
Separate Identity From Diagnosis
A diagnosis describes a health problem, not everything about you.
Replace Labels With Facts
Describe behavior accurately without converting it into a permanent identity.
Use Recovery Support
Contact with other people in recovery can challenge the belief that change is impossible.
Repair What Can Be Repaired
Responsibility can involve apology, restitution and changed behavior without permanent self-condemnation.
What Actually Helps Reduce Substance Use Stigma?
Simply telling people to “be less judgmental” is unlikely to create lasting change.
Stigma reduction works best when people are given accurate information, opportunities to reconsider stereotypes and meaningful contact with people whose real lives contradict those stereotypes.
Correct Inaccurate Beliefs
Explain substance use disorders, treatment, recovery and medication using accurate clinical information.
Make Recovery Visible
Real contact with people in recovery can challenge stereotypes that addiction is permanent or defines an entire person.
Remove Structural Barriers
Policies and clinical processes should make treatment easier to access rather than requiring people to prove they are worthy of care.
Earlier systematic-review evidence found promising effects from education, direct contact, professional training and selected therapeutic interventions.
More recent reviews continue to identify provider stigma and internalized stigma as targets for intervention.
Read the 2024 Healthcare Stigma Review →What Healthcare Professionals Can Do
Use Person-First Language
Write “person with opioid use disorder” rather than reducing the patient to a stigmatizing label.
Document Behavior, Not Character
Instead of describing somebody as manipulative or difficult, document what actually occurred and the clinical concerns.
Offer Evidence-Based Treatment
Treatment decisions should be based on clinical indication and patient preference rather than moral judgments about medications.
Expect Recovery to Be Nonlinear
A return to substance use can signal a need to reassess treatment rather than proof that the person is incapable of recovery.
Ask What Matters to the Patient
Recovery goals, medication preferences, family circumstances and previous treatment experience should be part of shared decision-making.
Make Access Easier
Low-barrier, welcoming treatment can reduce the practical and psychological obstacles that cause people to disengage.
Ask: “Would I use this same tone and terminology if the patient had diabetes, cancer or another chronic health condition?”
What Families Can Do to Reduce Stigma
Supporting treatment does not require protecting somebody from every consequence of harmful behavior.
Arguments should focus on behavior and boundaries rather than dehumanizing labels.
Do not pressure somebody to discontinue methadone, buprenorphine or another medication merely because the family dislikes the idea of medication-assisted recovery.
Recovery may involve improved health, fewer high-risk behaviors, treatment engagement, employment, repaired relationships and increased stability.
Relatives can seek counseling, family support or professional advice rather than carrying the entire problem alone.
If overdose is suspected, respond medically first. Discussions about consequences can happen after the person is safe.
Why Real Recovery Stories Matter
Stigma survives partly because addiction is often most visible during crisis.
People see an overdose, an arrest, homelessness or family conflict.
Recovery is quieter.
A person may return to work, rebuild a relationship, attend counseling, take medication, raise children, exercise, study or simply live an ordinary life.
Those ordinary outcomes rarely become headlines.
A diagnosis is not a forecast of somebody’s permanent identity. People can change substantially when treatment, time, support and opportunity are available.
Stories Should Not Become Another Standard People Must Meet
There is also a risk in presenting only extraordinary recovery stories.
Somebody should not have to become a motivational speaker, entrepreneur or public advocate to prove that recovery is valid.
Quiet stability is also success.
A Practical Plan for Reducing Substance Use Stigma
Notice Your Automatic Language
Pay attention to words such as addict, junkie, clean, dirty, drug abuser or replacement therapy.
Replace Labels With Clinical Description
Describe the diagnosis, behavior or laboratory result directly.
Separate the Person From the Harm
Harmful behavior can be confronted without declaring that the entire person is permanently harmful.
Learn the Evidence
Understand how addiction, withdrawal and evidence-based medications actually work.
Listen to People in Recovery
Real-world contact can challenge stereotypes more effectively than abstract assumptions.
Change Systems, Not Only Words
Review policies, access barriers and clinical processes that may disadvantage people with substance use disorders.
Reducing stigma is not about making addiction seem harmless. It is about making treatment, accountability and recovery possible without dehumanizing the person.
Substance Use Stigma Knowledge Quiz
This 20-question educational quiz tests what you have learned from the article.
Only one question appears at a time, so the quiz remains compact on desktop and mobile.
This quiz is educational. It does not assess whether an individual has a substance use disorder or determine treatment suitability.
Reducing Stigma Around Substance Use Disorders: FAQ
1. What is stigma around substance use disorders?
It refers to negative labels, stereotypes and judgments attached to people because of substance use or a substance use disorder.
2. Why is addiction stigma harmful?
Stigma can contribute to shame, social isolation, discrimination and reluctance to seek or remain in treatment.
3. Is reducing stigma the same as excusing harmful behavior?
No. Harmful behavior can require consequences, boundaries and accountability. Reducing stigma means addressing those behaviors without dehumanizing the person.
4. Why is “person with a substance use disorder” preferred?
Person-first language separates the individual from the diagnosis and avoids defining an entire person by one health condition.
5. Is it always wrong for somebody to call themselves an addict?
No. Individuals may choose identity terms that have personal meaning, including within mutual-help programs. Medical organizations should avoid imposing stigmatizing labels on people who have not chosen them.
6. Why should clinicians avoid the term “drug abuser”?
The term can carry negative and punitive associations. More precise language describes the person, diagnosis or behavior directly.
7. Why are “clean” and “dirty” poor terms for drug tests?
Laboratory results are positive or negative. Calling a result clean or dirty can imply that the person’s moral worth is connected to the test.
8. What is public stigma?
Public stigma refers to negative beliefs and stereotypes held by society about people with substance use disorders.
9. What is structural stigma?
Structural stigma occurs when policies, systems or institutional practices create disadvantages for people affected by substance use disorders.
10. What is self-stigma?
Self-stigma occurs when a person internalizes negative social beliefs about addiction and begins applying them to themselves.
11. Can healthcare professionals stigmatize patients?
Yes. Research has documented stigmatizing attitudes toward substance use disorders among healthcare professionals and trainees, which is why provider education is an important anti-stigma strategy.
12. Is methadone simply replacing one addiction with another?
No. Methadone is an evidence-based medication for opioid use disorder. Medical treatment should not be equated with uncontrolled opioid use simply because the medication acts on opioid receptors.
13. Is buprenorphine a legitimate recovery medication?
Yes. Buprenorphine is an evidence-based medication for opioid use disorder and can reduce withdrawal and craving in appropriately treated patients.
14. Is naltrexone different from methadone and buprenorphine?
Yes. Naltrexone is an opioid receptor antagonist rather than an opioid agonist. It blocks opioid effects while adequate antagonist exposure is present.
15. Does choosing naltrexone make somebody “more recovered”?
No. Different medications use different pharmacological strategies. Recovery should be judged by health, functioning and treatment outcomes rather than moral status attached to a medication.
16. Are naltrexone implants FDA-approved in the United States?
No. The FDA-approved long-acting naltrexone formulation for opioid use disorder in the United States is extended-release intramuscular naltrexone. Implant products have different regulatory status in other settings.
17. Why does someone need assessment before naltrexone?
A patient who is still physiologically dependent on opioids can experience precipitated withdrawal if naltrexone is started too soon. Appropriate opioid-free preparation and clinical assessment are therefore necessary.
18. Can families reduce stigma while maintaining boundaries?
Yes. A family can refuse unsafe behavior, protect finances, enforce household rules and encourage treatment without using dehumanizing labels.
19. Do recovery stories help reduce stigma?
Contact with people who have lived experience of recovery can challenge stereotypes, particularly when combined with accurate education.
20. What is the simplest thing I can do to reduce stigma?
Describe people, behaviors and diagnoses accurately rather than using labels that turn a health condition into somebody’s entire identity.
Addiction Treatment Should Not Require Shame
People can take responsibility for harmful behavior while still receiving dignified, evidence-based treatment.
If opioid dependence is part of the problem and you want to understand whether long-acting naltrexone could fit your recovery goals, DeBinge can explain the treatment, preparation requirements and ongoing recovery support.
A consultation is designed to understand the individual rather than define them by their addiction history.
Scientific References and Further Reading
This article draws on current SAMHSA, NIH and NIDA guidance together with peer-reviewed systematic reviews of substance-use stigma and stigma-reduction interventions.
SAMHSA — Stigma and Language
Current SAMHSA resource explaining how negative perceptions, language and shame can interfere with treatment and recovery.
Read SAMHSA Guidance →NIDA — Words Matter
Practical guidance on preferred terminology for discussing addiction and substance use disorders.
Read NIDA’s Words Matter Guide →NIH — Person-First and Destigmatizing Language
NIH style guidance explaining person-first language and the importance of avoiding language that reduces a person to a diagnosis.
Read NIH Guidance →NIH — Alcohol and Substance Use Terminology
NIH recommendations for clinically accurate and non-stigmatizing language about substance use and recovery.
Read NIH Substance Use Language Guidance →SAMHSA — Breaking Down Barriers to Treatment
SAMHSA information about low-barrier models of substance-use treatment and reducing judgment and structural obstacles.
Explore SAMHSA’s Barrier-Reduction Resources →Livingston et al. — Stigma Reduction Systematic Review
Systematic review of interventions designed to reduce stigma associated with substance use disorders.
Read on PubMed →Magnan et al. — Healthcare Professional Stigma Review
2024 systematic review of stigma toward patients with substance use disorders among healthcare professionals and trainees.
Read on PubMed →Sibley et al. — Interventions to Reduce Self-Stigma
2024 systematic review examining interventions intended to reduce internalized stigma among people who use drugs.
Read on PubMed →Cernasev et al. — Treatment Access, Adherence and Stigma
Systematic literature review examining patient perspectives on treatment barriers, stigma and persistence in care.
Read on PubMed →FDA — Medications for Opioid Use Disorder
FDA information on methadone, buprenorphine and naltrexone as medications used to treat opioid use disorder.
Read FDA MOUD Information →SAMHSA TIP 63 — Naltrexone
Clinical guidance on naltrexone pharmacology, opioid-free preparation and patient selection.
Read the Naltrexone Chapter →Stigma and Opioid Use Disorder Treatment
Review examining how opioid-related stigma affects treatment, harm reduction and policy.
Read on PubMed →Language recommendations evolve. Person-first terminology is a useful default for clinical and public communication, but individual people and recovery communities may choose different terms for themselves. Respecting that personal preference is also part of non-stigmatizing care.
Resources for healthcare professionals and treatment services.
Explore SAMHSA → NIDA Words MatterQuick guide to terminology that can reduce stigma.
Open NIDA Guide → NIH Substance Use Style GuidePreferred terminology for substance use and recovery.
Explore NIH → Dr Fergus LawClinical and scientific profile and addiction expertise.
View Profile →Prepared for medical review by Dr. Fergus Law, BSc, MBChB, FRCPsych
Consultant Psychiatrist specialising in substance misuse and addiction psychiatry
Review status: Pending clinical approval
This article provides educational information and does not replace individualized diagnosis or treatment from a qualified healthcare professional.